Dalargin for Health & Longevity

Evidence Review created on 10/25/2026 using AI4L / Opus 5.5

Also known as: Tyr-D-Ala-Gly-Phe-Leu-Arg, D-Ala2-Leu5-Arg6-Enkephalin, D-Ala2-Dynorphin 1-6, Leitragin, Leytragin, Ambervin Pulmo, Dalargin-Ellara, Dalargin-DEKO, Dalargin-Pharmsynthesis

Motivation

Dalargin is a laboratory-made copy of one of the body’s own small signalling molecules, altered at two points so that it survives longer in the bloodstream and stays outside the brain. It acts on the same cell-surface receptors that morphine-like substances use, but because it does not enter the brain it was developed as a tissue-protective and tissue-repair agent rather than a pain medicine. It is given by injection, by nose drops, or by nebulizer, never by mouth.

The compound was created in the early 1980s at the Soviet cardiology research centre in Moscow and is registered in Russia as a prescription injection for ulcers of the stomach and upper small intestine and for acute inflammation of the pancreas (label). A related inhaled version was registered in Russia in 2021 for lung complications of viral infection (label). Almost the entire clinical literature is Russian-language and dates from the 1980s and 1990s, and placebo-controlled trials have been completed only recently.

For health-focused adults weighing tissue-protective peptides, this review examines what the published human and animal evidence shows about dalargin’s effects, how strong that evidence is, what harms have been recorded, and how the compound has been dosed and monitored.

Benefits - Risks - Protocol - Conclusion

Recommended Reading

High-level sources that discuss dalargin, or the enkephalin-analogue class it belongs to, in substantial depth.

• To the noradrenergic component of the mechanisms of stress-limiting and healing effects of dalargin - Zabrodin, 2016

  The only recent narrative synthesis of dalargin’s stress-limiting and wound-healing literature, and the only source that argues the effects run through sympathetic nerve signalling rather than opioid receptors alone.

• Dalargin–the first enkephalin analog, used in gastroenterology - Vinogradov & Polonskiy, 1988

  A review by the drug’s own developers summarizing the first five years of gastroenterological use, giving the original rationale, dose-finding logic and indication set that later labels inherited.

• Activity profiles of dalargin and its analogues in mu-, delta- and kappa-opioid receptor selective bioassays - Pencheva et al., 1999

  The most rigorous receptor-pharmacology study of the molecule, mapping which structural features drive its receptor preference and resistance to breakdown enzymes.

• Neuropeptides in anesthesiology and intensive care - Slepushkin, 1997

  A narrative review of the surgical and intensive-care use of regulatory peptides including dalargin, the second-largest body of clinical experience with the compound.

Only four items are listed. None of the priority platforms has published anything on dalargin, and beyond these narrative reviews and primary pharmacology, the remaining material treats dalargin only as a model drug or in passing, so the list is not padded with it.

Grokipedia

No Grokipedia article on dalargin exists. The site’s search returns a single hit, its Leu-enkephalin article, and the direct page address reports “Not yet written”.

Examine

No Examine article on dalargin exists. Dalargin is a prescription injectable medicine rather than a dietary supplement, and Examine.com does not typically cover prescription medications.

ConsumerLab

No ConsumerLab article on dalargin exists. ConsumerLab tests retail supplements and foods and does not typically cover prescription medications, which is what dalargin is in every country where it is registered.

Systematic Reviews

No systematic reviews or meta-analyses for Dalargin were found on PubMed as of October 24, 2026.

The principal trade-off for this compound is tissue-protective benefit against blood-pressure lowering and allergic reaction. Neither side of that trade-off is represented: the literature provides no systematic review or meta-analysis of dalargin’s benefits and none of its harms.

Mechanism of Action

Dalargin is the hexapeptide Tyr-D-Ala-Gly-Phe-Leu-Arg: leucine-enkephalin with its second amino acid switched to the mirror-image D form and an arginine added. The mirror-image form resists the enzymes that destroy enkephalins within seconds (Pencheva et al., 1999), and the molecule does not cross into the brain, so it acts only on opioid receptors outside the central nervous system (Kreuter, 2015).

Which receptor matters is disputed. Bioassays found dalargin selective for mu-opioid receptors (the morphine-type) (Pencheva et al., 1999), its developers reported mainly delta binding (Titov et al., 1985), and its cardiac effects were traced to peripheral kappa-opioid receptors (Maslov et al., 2005). Downstream, dalargin suppresses protein-breakdown enzymes, stomach acid and pancreatic enzyme output (label), and raises DNA synthesis (the copying of genetic material before a cell divides) in gut lining cells (Zivotova et al., 2007); in kidney it phosphorylates GSK-3β (an enzyme switch controlling cell survival) (Plotnikov et al., 2013). A competing account holds the protection is indirect, restraining sympathetic nerve over-activity (Zabrodin, 2016).

It is short-lived: a human receptor-binding study described a fast phase of 1.5–5 minutes carrying 90% of activity and a slow phase of 85–200 minutes (Zaytsev et al., 1986); bioavailability in dogs was 15% by muscle injection and 8% by nose, with half-lives of 23.2 and 21.3 minutes (Vinogradov et al., 1988). Clearance is by peptide-cutting enzymes, not the liver CYP enzymes (cytochrome P450, the main drug-processing family): carboxypeptidase N strips the terminal arginine (Skidgel et al., 1984), leaving tyrosine and shorter fragments (Kalenikova et al., 1988).

Historical Context & Evolution

Dalargin was synthesized in the early 1980s at the All-Union Cardiology Research Centre in Moscow, now the National Medical Research Centre of Cardiology, which developed it, holds its marketing authorization and still manufactures it — developer, sponsor and manufacturer in one body, and the origin of most of the favourable literature (label). Enkephalins had just been discovered, and the design goal was a peptide that kept their tissue-protective actions while losing their brain effects and habit-forming potential. Screening of 22 analogues in a chemically induced rat ulcer model identified this hexapeptide as most active at 10–15 micrograms per kilogram, with no addiction or physical dependence observed (Smagin et al., 1984).

The original intended use was ulcer disease, and it became the first enkephalin analogue used in gastroenterology (Vinogradov & Polonskiy, 1988). Use then widened to acute pancreatitis, anesthesia, intensive care, burns and skin disease. Interest for health optimization followed from the claim that drove the original design: a peptide limiting stress-driven tissue damage and speeding repair without central opioid effects.

Soviet-era enthusiasm receded as acid-suppressing oral medicines and eradication of the ulcer bacterium made injectable ulcer treatment unnecessary, not because dalargin was shown ineffective — the single Western-standard trial compared it against an active drug rather than placebo (Dajani et al., 1991). The compound has since returned twice: as an inhaled form registered in Russia in 2021 (label), and in a placebo-controlled surgical trial completed in 2026 (NCT07404358). What changed was the comparator and the trial standard, not disproof.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: each human clinical endpoint rests on controlled trials from a single research group, without independent controlled replication.

Medium 🟩 🟩

Healing of Gastric and Duodenal Ulcers ⚠️ Conflicted

Endoscopically confirmed closure of stomach and duodenal ulcers is the outcome measured most often. The placebo comparison comes only from the developers (Smagin and colleagues, also against cimetidine); Georgadze and colleagues, with a developer as co-author, reported an uncontrolled bleeding-ulcer series; and Dajani and colleagues ran a multicentre double-blind randomized controlled trial (RCT, a study assigning participants to treatments by chance) without a placebo arm. That RCT found dalargin inferior to misoprostol. Net reading: healing occurs, but dalargin is weaker than a standard comparator.

Magnitude: 50 percentage points more healed ulcers at 4 weeks than placebo (80% versus 30%) and complete scarring in 87.5% by day 28, with mean healing of 21.4 ± 1.2 days versus 23.7 ± 1.8 days on cimetidine, no confidence interval (the range in which the true size of an effect most likely lies) or between-group test reported (Smagin et al., 1987); against misoprostol, dalargin healed significantly fewer ulcers (p = 0.0001, p being the probability that a difference this large would arise by chance; evaluable cohort, meaning only the patients with usable follow-up data; no rates given) (Dajani et al., 1991).

Reduced Opioid Requirement and Steadier Circulation During Major Surgery

Added to balanced general anesthesia, dalargin cut the amount of strong opioid needed while anesthetic depth was maintained, and lowered total peripheral vascular resistance. All of this work comes from one Moscow group (Likhvantsev, Shloznikov, Kuzin, Smirnova) across abdominal, lung and congenital heart surgery, which caps the grade at Medium despite the consistency. Liver enzyme and lipid-peroxidation measurements in the same patients were read as liver protection, but those are unvalidated markers.

Magnitude: Intraoperative use of strong opioid analgesics was 6-fold lower than with the conventional technique in 36 patients undergoing abdominal surgery, with equal anesthetic efficacy; no confidence interval reported (Likhvantsev et al., 1990).

More Favourable Blood Lipids and Stress Hormones in Coronary Heart Disease with Metabolic Syndrome

In 123 randomized patients with stable coronary heart disease and metabolic syndrome, adding intranasal dalargin to standard treatment shifted triglycerides, high-density lipoprotein (HDL, the cholesterol-carrying particle associated with lower cardiovascular risk), insulin, cortisol, leptin and the inflammatory signal interleukin-6 further than standard treatment alone. Oxidative-stress readouts in the same trial — superoxide dismutase (an enzyme that neutralizes a reactive form of oxygen), total antioxidant activity, oxidized low-density lipoprotein — are unvalidated markers and carry no weight here. Both reports come from a single investigator, Dontsov.

Magnitude: Standard therapy alone changed triglycerides by −17.4% and HDL cholesterol by +10.3%; with dalargin added the changes were −27.2% and +17.4%, with insulin −22.4% and cortisol −23.9% (p < 0.001, 123 patients, not compared between groups, no confidence intervals reported) (Dontsov, 2017; Dontsov, 2015).

Improved Exercise Tolerance in Advanced Atherosclerosis

In patients with narrowed leg and heart arteries, dalargin added to standard treatment improved walking capacity and clinical status and lowered lactate in venous blood draining the affected limb, alongside falls in cholesterol and parathyroid hormone. The work is confined to the Tomsk cardiology group (Zoloev, Dudko, Karpov, Maslov), one research group, and the trials were small and open-label.

Magnitude: Direction only — exercise tolerance and limb clinical indices improved, and the effect held in patients with stage II–III arterial occlusion given dalargin early in the course of combined treatment; the literature reports no outcome figure for the size of the change (Zoloev et al., 1990; Maslov et al., 2002).

Faster Recovery in Viral Pneumonia and Lower Respiratory Infection

The inhaled form is registered in Russia for moderate coronavirus infection on the ground that it damps the inflammatory signal interleukin-6 and the release of an inflammatory alarm protein in the lung (Karkischenko et al., 2021; Leitragin label). A single-blind placebo-controlled multicentre trial of the succinate salt of the same hexapeptide in community-acquired pneumonia reported faster clinical cure, as did an earlier open comparison against standard care in moderate coronavirus infection. Both were funded by the manufacturer, Promomed, and neither is indexed in PubMed.

Magnitude: Clinical cure by day 10 in 54.8% on the inhaled hexapeptide versus 36.1% on placebo, an 18.7 percentage-point difference, with clinical stability or discharge reached in 2.54 ± 0.89 versus 3.38 ± 1.64 days; no confidence intervals are reported (Avdeev et al., 2025; Balykova et al., 2022).

Low 🟩

Fewer Postoperative Pancreatic Complications ⚠️ Conflicted

A non-randomized surgical comparison reported less postoperative pancreatitis than with protease inhibitors (drugs that block protein-digesting enzymes). A much larger randomized three-arm comparison found the opposite ranking: the dalargin-plus-fluorouracil arm had the highest complication rate. Net reading: the controlled comparison does not support dalargin for preventing pancreatic complications.

Magnitude: Postoperative pancreatitis was 4.16-fold less frequent than with protease inhibitors in 48 patients, a non-randomized comparison with no confidence interval reported (Grigorevskiy et al., 1989); in a 594-patient randomized comparison, complications occurred in 22.4% on dalargin with fluorouracil versus 3.06% on long-acting octreotide, a 19.3 percentage-point excess, with deaths in 1.8% versus 1.02% and no confidence intervals reported (Chernousov et al., 2012).

Symptom and Course Improvement in Acute Pancreatitis

Acute pancreatitis and pancreatic necrosis (death of pancreas tissue) are the drug’s second registered indication, on the ground that it suppresses pancreatic enzyme output. Uncontrolled Russian series reported low mortality and faster settling, as did a series in flare-ups of long-standing pancreatitis. No series had a control group.

Magnitude: Mortality was 5.5% in 74 patients treated for fatty pancreatic necrosis, no control group and no confidence interval reported; the series in acute pancreatitis (126 patients) and in chronic pancreatitis flare-ups report no outcome figure (Georgadze et al., 1991; Pobutskyi, 2002; Geller et al., 1992).

Fewer Infectious Complications After Cardiac Surgery

Added to anesthesia in heart disease surgery, dalargin was followed by fewer and less severe post-operative pus-forming complications, including infection behind the breastbone, and fewer deaths from infection. The report is one group’s comparative series, not randomized or blinded, leaving it open to selection and period effects.

Magnitude: Direction only — the absolute number and percentage of infectious complications and deaths from them fell relative to the comparison series; the literature reports no outcome figure and the source gives no event rates for either group (Pashutin et al., 1993).

Faster Settling of Alcohol Withdrawal Symptoms

Twenty patients in alcohol withdrawal received dalargin by muscle injection twice daily for three days, with improvement attributed to shifts in several brain signalling systems. There was no control group and no replication. A separate trial found dalargin ineffective in severe depression, so the psychiatric signal is inconsistent.

Magnitude: Direction only — withdrawal symptoms improved over three days of treatment in 20 patients (no control group); the literature reports no outcome figure (Aliyev, 1992; Zozulia et al., 1994).

Added Lining Repair in Inflammatory Bowel Disease

In a randomized comparison in Crohn’s disease, mesalazine with dalargin normalized small-bowel lining structure more completely than mesalazine alone. The proliferation index and free-radical readouts are unvalidated tissue markers, not clinical endpoints, and the tissue reading was not quantified.

Magnitude: The proliferation labelling index fell from 24.05 ± 1.17% to 18.60 ± 1.18% with mesalazine alone and from 22.90 ± 0.92% to 14.38 ± 0.81% with dalargin added, a 4.2 percentage-point lower end value, not compared between groups and with no confidence intervals reported (Ozhegov et al., 2012).

Speculative 🟨

Protection of Kidney Tissue Against Drug-Induced Injury

In rats given the antibiotic gentamicin, dalargin reduced kidney tubule cell death and kidney dysfunction (Plotnikov et al., 2013; Cherpakov et al., 2015). No human outcome data exist; the basis is animal work only.

Protection of Stomach Lining Against Anti-Inflammatory Drug Damage

In rats given ibuprofen-type pain medicines, dalargin reduced stomach lining damage and restored DNA synthesis there (Zhivotova et al., 2009). The basis is animal work only.

Blunting of Cold- and Hypothermia-Related Oxidative Damage

In cooled rats, dalargin reduced free-radical activity (Tadzhibova et al., 2011), and in cultured cells it reduced cold-stress death (Moisieieva et al., 2023). Endpoints are unvalidated markers or cell culture.

Cardiac Rhythm Stabilization ⚠️ Conflicted

In rats, dalargin stopped chaotic heartbeats when blood flow returned, not during the blockage (Solenkova et al., 2005); twenty days’ dosing changed nothing (Lishmanov et al., 2008). Net reading: animal-only and absent with chronic dosing.

Benefit-Modifying Factors

• Genetic variation: No pharmacogenetic data exist for dalargin. The 2025–2026 surgical trial is the first to examine whether variants in NRF2, OLR1, TLR9, AGTR1 and AQP1 (genes governing antioxidant defence, oxidized-fat uptake, immune sensing, blood-pressure signalling and water transport) predict response (NCT07404358).

• Baseline beta-endorphin and stress-hormone levels: Low circulating beta-endorphin (the body’s own opioid) tracked with higher insulin, cortisol and inflammatory signals in coronary heart disease; the trial treated patients with that profile but did not test whether baseline level predicts response (Dontsov, 2017).

• Baseline severity of tissue injury: Lung-protective effects during heart surgery were larger where the pre-existing abnormality in lung vascular tone was more pronounced, suggesting the benefit scales with the deficit being corrected rather than adding to normal function (Likhvantsev et al., 1993).

• Sex: No sex-stratified result has been published. Trials enrolled both sexes in near-equal numbers (61 men, 62 women in the coronary trial), so a sex difference has not been excluded, only never examined (Dontsov, 2017).

• Pre-existing conditions: Ulcers scarred early in most patients, but stomach- and duodenal-lining inflammation persisted where the ulcer bacterium was abundant and antibody titres high, so unresolved infection limits that part of the response (Lukash et al., 1992).

• Age: No age-stratified analysis exists. Labels restrict use to adults, and trials have enrolled up to age 80 and 85, so evidence covers the older end of the adult range only as part of pooled results (NCT07404358).

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: the human harm data are label listings and uncontrolled hemodynamic studies, and no controlled trial reports an adverse-event rate against a comparison group.

Medium 🟥 🟥

Fall in Blood Pressure, with Dizziness and Blurred Vision

Blood-pressure lowering is the best-documented harm and is listed on every label. Intravenous dalargin produced a hypotensive response in heart-attack patients (Tomsk group), and a Moscow surgical group recorded lower peripheral vascular resistance under anesthesia. Labels attribute the dizziness and disturbed visual perception to this pressure drop and warn against driving; the Ukrainian label also lists headache. No controlled trial has measured the rate or size of the fall, which holds the grade at Medium.

Magnitude: Direction only — blood pressure falls after intravenous dosing, most clearly at 0.1 mg/kg in patients with recent heart attack, and labels grade the reaction as rare for the injectable form; the literature reports no outcome figure for the size of the fall and the sources give no comparison-group rate (Maslov et al., 2008; Likhvantsev et al., 1990; label).

Heart-Rate Disturbance in Both Directions

Dalargin changes heart rate unpredictably: it slowed the heart through peripheral kappa-opioid receptors and delayed conduction at the junction between the heart’s upper and lower chambers in isolated hearts, yet produced a faster heart rate in some intact animals and in patients, an effect abolished by blocking autonomic ganglia. The Ukrainian label lists rapid heart rate and palpitations. All the mechanistic work comes from one group (Maslov, Tomsk), which holds the grade at Medium.

Magnitude: Direction only — heart rate may fall or rise after intravenous dosing depending on autonomic tone, and conduction slows with direct cardiac exposure; the literature reports no outcome figure and the sources give no comparison-group rate (Maslov et al., 2005; Maslov et al., 2008; label).

Low 🟥

Allergic and Infusion-Type Reactions ⚠️ Conflicted

Allergic reactions appear on all labels. The broadest adds rash, itching, hives, facial flushing and swelling, chills, fever, chest pain, numbness of face and limbs, and laboured breathing with choking — a histamine-type reaction to an injected peptide. A 45-patient series recorded no side effects. Net reading: real but uncommon.

Magnitude: Labelled as rare for the injectable form, meaning at least 1 in 10,000 and fewer than 1 in 1,000 treated patients, with frequency not estimable for the inhaled form; no comparison-group rate is given in any source (Leitragin label; Dalargin-Pharmsynthesis label; Smagin et al., 1984).

Nausea and Upper Abdominal Pain ⚠️ Conflicted

The Ukrainian label lists nausea and abdominal pain. This sits oddly beside the drug’s indication: in rats it protected the stomach lining from anti-inflammatory drug damage, and in ulcer patients it raised repair activity there. Net reading: the evidence weighs toward lining protection.

Magnitude: Not quantified in available studies. The label assigns no frequency category to the gastrointestinal reactions, and no controlled trial has reported nausea or abdominal pain rates with a comparison group (label; Zhivotova et al., 2009; Timoshin et al., 1991).

Speculative 🟨

Unpredictable Immune Modulation

Laboratory work showed effects on immune-cell growth in both directions (Zozulia et al., 1994), and stressed rats showed shifted bone-marrow white cells (Garmaeva, 2022). No human immune outcome exists.

Loss of Effect at Higher Doses

The developers reported the protective effect “escapes” as the dose rises above 10 micrograms per kilogram in animals, making higher dosing counterproductive (Titov et al., 1985). The basis is animal work only.

Carrier-Related Toxicity in Brain-Delivery Formulations

Experimental particles carrying dalargin into the brain produce pain-blocking effects, which one group attributed to carrier toxicity to the brain’s protective barrier (Olivier et al., 1999). This risk belongs to the carrier, not registered dalargin.

Risk-Modifying Factors

• Genetic variation: No variant is known to modify dalargin’s harms. Clearance depends on blood and membrane peptide-cutting enzymes, chiefly carboxypeptidase N, rather than on the liver CYP enzymes that carry most pharmacogenetic risk (Skidgel et al., 1984).

• Baseline blood pressure: Low blood pressure is an absolute label contraindication because the drug’s own mild pressure-lowering action is additive; a low starting pressure converts a minor effect into symptomatic hypotension (label).

• Sex: No sex difference in adverse reactions has been reported. Labels make no sex distinction and no trial has published sex-stratified safety data, so a difference is unexamined rather than excluded (label).

• Pre-existing conditions: Active infectious disease is a label contraindication, as is pregnancy; the same label states that safety during breastfeeding is unestablished rather than reassuring (label).

• Severe organ or cardiac disease: The surgical trial excluded the most severe heart failure class, kidney disease of stage 3a or worse, recent heart attack or stroke, and the two highest surgical risk classes — the clearest statement of who was too fragile (NCT07404358).

• Age: Two labels restrict use to adults aged 18 and over; the other two only note that paediatric data are absent. None adjusts the dose for older adults, and one states that data on adults with chronic illness are absent (label; label).

Key Interactions & Contraindications

• Opioid analgesics (morphine, fentanyl, oxycodone): Caution. Labels state dalargin strengthens the action of narcotic analgesics, and surgical use exploited this to cut intraoperative opioid dose 6-fold; the clinical consequence of not reducing the opioid is excessive sedation and breathing suppression (label; Likhvantsev et al., 1990).

• Opioid blockers (naloxone, naltrexone): Avoid together. Labels state naloxone blocks the anti-ulcer action of dalargin and the effects of the inhaled form, so the clinical consequence is complete loss of benefit (label).

• Blood-pressure-lowering medicines (captopril, enalapril, amlodipine): Monitor. In 87 patients with high blood pressure, dalargin given by nasal electrophoresis strengthened captopril’s pressure-lowering effect and reduced noradrenaline output; the consequence is excessive hypotension (Kuriata, 1999).

• Acid-suppressing medicines (famotidine, cimetidine): Caution for additive effect, not harm. In 75 patients with duodenal ulcer, dalargin combined with famotidine produced the largest increase in lining repair activity of any regimen tested (Alekseenko & Timoshin, 1996).

• Antacids (aluminium and magnesium salts): No interaction reported. The Ukrainian label instructs that antacids be given alongside dalargin where pain is prominent, so co-use is intended rather than avoided (label).

• Over-the-counter anti-inflammatory pain medicines (ibuprofen, naproxen, aspirin): Caution (theoretical). No human interaction study exists; in rats dalargin reduced the stomach-lining damage these drugs cause, so the direction of any interaction is protective rather than harmful (Zhivotova et al., 2009).

• Over-the-counter sedating antihistamines (diphenhydramine, doxylamine): Caution (theoretical). No study exists; the concern is additive drowsiness and dizziness layered on the labelled pressure-lowering effect, with falls as the consequence (label).

• Supplements that lower blood pressure (magnesium, beetroot or other nitrate sources, garlic extract, L-arginine): Caution (theoretical) for additive hypotension. No interaction study exists; these are flagged because they share the one labelled cardiovascular effect dalargin has (label).

• Aminoglycoside antibiotics (gentamicin, tobramycin): No interaction expected (theoretical). No human study exists; in rats dalargin reduced gentamicin kidney injury rather than worsening it, so the direction of any interaction is protective and no dose change is implied (Plotnikov et al., 2013).

• Solvents other than 0.9% sodium chloride: Absolute contraindication of use. Labels state incompatibility with any diluent not named in the dosing section; the consequence is loss of the product (label).

• Mitigating actions: The labelled opioid potentiation is managed in practice by lowering the co-administered opioid dose rather than the dalargin dose, with blood pressure measured around the first doses when a pressure-lowering medicine is in use; naloxone cancels the effect (label).

Populations who should avoid Dalargin:

• Anyone with known hypersensitivity to the active substance (label)
• People with low blood pressure; one label specifies pronounced arterial hypotension, and a trial of the inhaled form set the limit at below 100/60 mm Hg (label; NCT05656495)
• People with an acute infectious process (label)
• Pregnant and breastfeeding women (label)
• Anyone under 18 years of age (label)
• People with heart failure of New York Heart Association class IV (symptoms at rest) or chronic kidney disease of stage 3a or worse on the KDIGO (Kidney Disease: Improving Global Outcomes) staging system, meaning filtration below 60 (NCT07404358)
• People with heart attack or stroke within the past 6 months, or surgical risk class IV–V on the American Society of Anesthesiologists scale (NCT07404358)
• People with a diagnosed psychiatric or neuromuscular disorder, by the same trial’s exclusion criteria (NCT07404358)

Risk Mitigation Strategies

Doses, timings and thresholds below follow common practice unless cited.

• Blood-pressure check before and after dosing: Sitting and standing pressure is taken before the first dose and 30 minutes after, since the labelled pressure fall is the one harm documented across all sources (label).

• Withhold at a low starting pressure: Arterial hypotension is an absolute label contraindication, and a trial of the inhaled form withheld treatment below 100/60 mm Hg; this prevents the additive drop that produces dizziness and visual disturbance (label; NCT05656495).

• Start at the lower end of the labelled range: A 1 mg rather than 2 mg first injection, within the 5 mg daily ceiling, limits the pressure fall and any hypersensitivity reaction (label).

• First dose under observation: The first dose is given where staff and resuscitation equipment are present, because labelled reactions include facial swelling, laboured breathing and a sense of choking consistent with a histamine-type reaction (label).

• No driving or hazardous activity during a course: Labels specifically advise avoiding activities needing sharp attention and fast reactions because the pressure fall can cause dizziness and blurred vision, with falls and crashes as the consequence (label).

• Defer treatment during acute infection: Acute infectious processes are a label contraindication; postponing the course until the infection resolves avoids the uncharacterized interaction with an active immune response (label).

• Reduce opioid dose when used together: Where strong opioids are given concurrently, their dose is cut at the outset rather than titrated upward, since dalargin strengthens their effect and the risk is breathing suppression (label).

• Reconstitute only in 0.9% sodium chloride: The freeze-dried powder is dissolved in 1 mL of 0.9% sodium chloride immediately before injection; other diluents are declared incompatible and risk a degraded or precipitated product (label).

• Keep courses to labelled length: Courses stop at 3–4 weeks for ulcer indications, 4–6 days for acute pancreatitis and 2–6 days for pancreatic necrosis; no safety data exist beyond these durations (label).

• Cold-chain storage check: The solution is stored at 4–8 °C, protected from light (Mikrogen label), and the freeze-dried powder below 20 °C (Cardiology Centre label); a broken cold chain degrades a peptide that has no preservative.

Therapeutic Protocol

Doses below are each cited to their source. Other parameters without a citation — timing within the day, course spacing and titration steps — reflect common practice.

• Ulcer-disease regimen: 1–2 mg into muscle or vein per dose, maximum 5 mg daily, for 3–4 weeks, 30–50 mg total per course; the freeze-dried form’s own label gives 1 mg per dose (Mikrogen label; Cardiology Centre label).

• Acute pancreatitis regimen: 2 mg into a vein first, then 5 mg once or twice daily for 4–6 days; for pancreatic necrosis, 5 mg into a vein every 6–8 hours for 2–6 days (label).

• Competing approach — nasal route: 1 mg into the nose twice daily for 10 days, repeated three times over three months, in coronary disease with metabolic syndrome; nasal bioavailability is 8% against 15% (Dontsov, 2015; Vinogradov et al., 1988).

• Competing approach — continuous infusion: 30 mg diluted to 300 mL, infused at 0.8 mg per hour for 24 hours then 0.4 mg per hour for 48 hours, starting after anesthesia induction, is the perioperative organ-protection regimen (NCT07404358).

• Competing approach — inhalation: 1 mg/mL by nebulizer over 30 minutes to 1 hour once daily for 10 days, with less than 10% reaching the bloodstream; this form is restricted to inpatient use (Leitragin label).

• Alcohol-related regimens: 1 mg into a vein in 10 mL of 0.9% sodium chloride for alcohol-related mental disturbance per label; 1 mg into muscle twice daily for 3 days in the withdrawal series (label; Aliyev, 1992).

• Who popularized each approach: The injectable regimens come from the Moscow cardiology centre team of Smagin, Vinogradov, Bulgakov and Titov, which developed the compound; the surgical infusion from Malyshev’s Botkin hospital group (Smagin et al., 1987; NCT07404358).

• Best time of day: No human timing study exists. In mice, the brain uptake of carrier-bound dalargin varied with time of day, so timing may matter for delivery but the registered forms act outside the brain (Kreuter, 2015).

• Half-life in the body: Elimination half-life was 23.2 minutes after muscle injection and 21.3 minutes by nose in dogs; a human receptor-activity study described 90% of activity clearing in 1.5–5 minutes (Vinogradov et al., 1988; Zaytsev et al., 1986).

• Single versus split dosing: Labels split muscle injections into two daily doses and give intravenous doses once daily; the very short half-life is the reason continuous infusion was chosen for the surgical trial (label).

• Never by mouth: No oral form is registered and oral absorption has never been measured in people; the D-alanine substitution resists digestive enzymes in laboratory testing, so the limit is untested uptake rather than proven breakdown (Akimov et al., 2010).

• Genetic variants influencing dose: None established. The surgical trial is the first to test whether NRF2, OLR1, TLR9, AGTR1 and AQP1 variants predict response, with results not yet posted (NCT07404358).

• Sex-based dosing differences: None reported. No label distinguishes by sex and no trial has published a sex-stratified dose-response, so the same regimen is used for both (label).

• Age-related considerations: Use is adults only; trials enrolled to age 80 and 85 without a dose reduction for older participants, and one label states no information exists on use in adults with chronic illness (label; NCT07404358).

• Baseline measurements influencing response: Blood pressure sets eligibility; low baseline beta-endorphin with high insulin and cortisol characterized the treated coronary population, but no analysis tested whether these baselines predict response (Dontsov, 2017).

• Pre-existing conditions influencing response: Lining inflammation persisted despite early ulcer scarring where the ulcer bacterium was abundant with high antibody titres, and acute infection bars treatment outright (Lukash et al., 1992).

Discontinuation & Cycling

• Short courses only, never lifelong: Every registered regimen is finite — 3–4 weeks for ulcer disease, 4–6 days for acute pancreatitis, 2–6 days for pancreatic necrosis, 10 days by inhalation — and no label describes maintenance use (label).

• No withdrawal effects reported: No label lists a withdrawal or rebound reaction, and the original animal work found neither addiction nor physical dependence, consistent with a molecule that does not enter the brain (Smagin et al., 1984).

• No tapering protocol: No label specifies a taper, and with an elimination half-life near 20 minutes the drug is gone within hours of the last dose, so stopping is abrupt by design (Vinogradov et al., 1988).

• Cycling as it was actually used: The coronary trial repeated 10-day courses three times across three months rather than dosing continuously, the only published cycling schedule (Dontsov, 2015).

• Stopping alongside other drugs: Where dalargin was combined with acid suppression or standard cardiac treatment, dalargin was the agent stopped at the end of its course while the background treatment continued (Alekseenko & Timoshin, 1996).

Sourcing and Quality

• Prescription-only, no consumer channel: All registered forms are prescription medicines dispensed in ampoules; there is no supplement-grade or retail version, and no third-party testing programme covers the compound (label).

• Named manufacturers: The freeze-dried form is made by the National Medical Research Centre of Cardiology in Moscow, which also holds the registration; solutions are made by Mikrogen, and Dalargin-Pharmsynthesis is manufactured by Lekhim-Kharkiv (label; label).

• What to look for on the package: A registration number (P N001319/01 for the freeze-dried form, LS-000652 for the Mikrogen solution, UA/9163/01/01 for the Ukrainian product), the 1 mg or 1 mg/mL strength, and an in-date cold-chain label (label).

• Formulation differences matter: The freeze-dried powder keeps 5 years below 20 °C (Cardiology Centre label); the ready solution keeps 3 years at 4–8 °C (Mikrogen label); the inhalation solution keeps 18 months at 2–8 °C (Leitragin label).

• Purity and identity: An acetic-acid odour is specified as acceptable because the active substance is a diacetate salt; chromatographic methods exist to separate dalargin from its structural analogues and synthesis by-products, but no pharmacopoeial monograph is published outside Russia (label; Abbood et al., 2017).

• Research-chemical material is not a substitute: The registered ampoules are prescription-only and made to a stated composition and specification (Mikrogen label); material sold for laboratory use carries no registration number, sterility assurance or identity guarantee.

Practical Considerations

• Time to effect: Ulcer closure took a mean of 21–22 days across series, with most healing by day 28; pancreatitis courses run 4–6 days; marker changes in coronary disease were measured after 10-day courses over three months (Smagin et al., 1987).

• Pitfall — expecting brain effects: Dalargin was deliberately designed not to enter the brain, so mood, pain or sleep effects are not expected from the registered forms; only experimental carrier preparations produced central effects (Kreuter, 2015).

• Pitfall — assuming oral dosing works: No registered form is swallowed and no human study has measured oral uptake; laboratory work found the molecule resists digestive enzymes rather than being destroyed by them (Akimov et al., 2010).

• Pitfall — confusing the two products: The inhaled form carries the same active substance but a different registration, indication and restriction to hospital use; its data do not transfer to the injection (Leitragin label).

• Pitfall — treating old open-label results as settled: Most favourable reports were open-label series from the developing institution; the one blinded head-to-head trial favoured the comparator (Dajani et al., 1991).

• Regulatory status: Registered as a prescription medicine in Russia and Ukraine only, the inhaled form under the Russian emergency-situation procedure on limited clinical data. There is no United States or European Union approval, so use there sits outside any regulatory framework (label).

• Payer incentives favour the oral alternatives: The same ulcer indication is served by cheap oral generics, so insurers and national health systems have no financial reason to fund trials of an injected alternative — a structural bias in which questions get studied.

• Cost and access: Russian pharmacy listings run roughly 658–1,251 roubles for ten ampoules, inexpensive in itself, but access requires a Russian or Ukrainian prescription and a cold chain, which is the real barrier outside those countries (label).

Interaction with Foundational Habits

• Sleep: No direct interaction. The molecule does not cross into the brain and no label lists sedation or insomnia; the indirect route is the labelled blood-pressure fall, which can cause dizziness on rising at night, so dosing earlier in the day and standing up slowly are the practical considerations (label).

• Nutrition: Direct and blunting. Dalargin suppresses the pancreas’s secretion of digestive enzymes in response to food and to the gut hormone secretin, so it damps the normal post-meal pancreatic response; in pancreatitis use this is the intended effect, and in ulcer regimens injections were given independently of meals (label).

• Exercise: Indirect and potentiating in one setting. Walking capacity improved in patients with narrowed leg and heart arteries given dalargin with standard treatment. Against that, the labelled pressure fall argues for separating a dose from hard exertion and from hot showers afterwards (Maslov et al., 2002; label).

• Stress management: Direct and blunting of the stress-hormone response. Added to standard cardiac treatment, dalargin was followed by lower cortisol and lower inflammatory signals, and the narrative literature frames its whole profile as restraint of sympathetic over-activity; the practical point is that it overlaps with, rather than replaces, stress-reduction practice (Dontsov, 2017; Zabrodin, 2016).

Monitoring Protocol & Defining Success

Before a course, the baseline deciding eligibility is blood pressure measured sitting and standing, since low pressure is an absolute contraindication, together with heart rate and a check for active infection. Where the indication involves the pancreas, serum amylase and lipase are drawn at baseline, and where an organ-protection rationale is being tested, kidney filtration is measured because advanced kidney disease was an exclusion in the only placebo-controlled trial. Metabolic baselines worth capturing are fasting insulin and the triglyceride and high-density lipoprotein fractions, the markers that moved in the coronary trial.

During a course, blood pressure and heart rate are checked before and about 30 minutes after each of the first few doses, then daily. Pancreatic enzymes are repeated daily through a 4–6 day course. Metabolic and inflammatory markers are repeated at the end of a 10-day course and again after three months, the interval the published schedule used.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Blood pressure (sitting and standing)	No established target; track change from the individual’s own baseline	Safety check: the labelled pressure fall is the one consistently documented harm, and low pressure bars treatment	Measure before and 30 minutes after the first doses. Guideline treatment targets are not reference ranges, so none is given here. Hypotension is an absolute contraindication (label)
Heart rate	60–100 beats/min at rest (standard reference range)	Safety check: rate may fall or rise unpredictably, and conduction between the heart’s chambers can slow	Record at the same visits as blood pressure, tracking change from the individual’s own baseline. Both slowing and speeding are described (Maslov et al., 2005)
Serum amylase and lipase	Amylase 25–125 U/L and lipase 0–160 U/L (standard reference range)	Expected to change: the drug suppresses pancreatic enzyme output and was used to reduce enzyme excess	Assay-dependent; use the reporting laboratory’s own range. Requires no fasting. Relevant only where a pancreatic indication is in play (label)
Fasting insulin	2–25 µIU/mL (standard reference range)	Expected to change: insulin fell with added dalargin in the coronary trial, and insulin resistance is a trial endpoint	8–12 hour fast; draw with glucose so insulin resistance can be derived. HOMA-IR is the insulin-resistance index calculated from the pair (Dontsov, 2017)
Triglycerides and high-density lipoprotein cholesterol	No established target; track change from the individual’s own baseline	Expected to change: both fractions moved further with added dalargin than with standard treatment alone	Desirable lipid values are guideline targets rather than reference ranges, so none is given. Fast 9–12 hours; pair with the full lipid panel (Dontsov, 2017)
Interleukin-6	No established target; track change from the individual’s own baseline	Expected to change: this inflammatory signal is the declared mechanism of the inhaled form and fell in the coronary trial	Assays are not interchangeable; keep to one laboratory. Draw in the morning, as levels vary across the day (Leitragin label)
Estimated kidney filtration rate	No established target; track change from the individual’s own baseline	Safety check: advanced kidney disease excluded participants from the only placebo-controlled trial	Filtration below 60, stage 3a or worse on the KDIGO kidney-disease classification, was an exclusion criterion (NCT07404358)

Qualitative markers worth tracking alongside the laboratory values:

• Light-headedness or blurred vision on standing, the symptomatic face of the labelled pressure fall
• Upper abdominal pain, heartburn and nausea, the symptoms the ulcer indication targets and that the label also lists as reactions
• Redness, rash or itching at the injection site, and any facial flushing or swelling after a dose
• Chills, fever or chest tightness within an hour of a dose
• Walking distance before leg or chest discomfort, where circulation is the reason for use
• Day-to-day energy and sense of stress load, given the stress-hormone changes reported

Emerging Research

• Placebo-controlled perioperative organ-protection trial: NCT07404358 randomized 200 high-risk abdominal-surgery patients to a 72-hour dalargin infusion or saline, quadruple-blinded, and completed September 2026 with no results posted. A positive composite result would give dalargin its first modern High-tier benefit; a null result would undercut the whole organ-protection case.

• Registered but unpublished coronavirus trial: NCT04346693 randomized 320 hospitalized patients across four arms and completed November 2020, open-label, with no results posted six years later. Publication would show whether the trial behind the registration supports it; continued silence leaves that registration resting on unpublished data.

• Published trials of the succinate salt: NCT05656495 randomized 313 hospitalized patients to the inhaled or injected succinate against standard care, completed November 2022, and reported faster clinical improvement (Balykova et al., 2022); a placebo-controlled pneumonia trial followed (Avdeev et al., 2025).

• Developer claims awaiting publication: The Russian Federal Medical-Biological Agency, which developed, holds the registration for and sponsored the trials of the inhaled form, states that its phase 3 trial cut recovery and hospital time by about half again with no serious adverse events. This is a sponsor press statement, not peer-reviewed data.

• Replication of ulcer healing against placebo: No placebo-controlled ulcer trial has been run since the 1980s, and the one blinded trial used an active comparator (Dajani et al., 1991). A modern placebo-controlled endoscopic trial could move the ulcer-healing benefit in either direction.

• Brain-delivery platforms: Carrier systems continue to use dalargin as the test peptide (Migone et al., 2020; Rousselle et al., 2003). Success would create a different drug with central effects and a different risk profile; failure leaves the peripheral-only profile intact.

• Kidney and organ preconditioning: Animal kidney-protection findings (Plotnikov et al., 2013) have not reached human trials. Human confirmation would lift a Speculative item; repeated failure would confine the claim to rodents.

• Analytical groundwork: A validated blood-plasma assay now exists that uses dalargin as its internal standard (Fisher et al., 2022), which makes the human pharmacokinetic study the label says was never done technically feasible for the first time.

Conclusion

Dalargin is a short-lived laboratory copy of one of the body’s own opioid-like signalling molecules, modified so that it resists breakdown and stays out of the brain. It is given by injection, nose or nebulizer, and it is a registered prescription medicine only in Russia and Ukraine. Its evidence base is unusual: large in volume, almost entirely Russian-language, mostly from the 1980s and 1990s, and mostly produced by the state cardiology institute that invented the compound, holds its licence and manufactures it — a conflict of interest that runs through the favourable literature, with the agency behind the inhaled form in a comparable position. Competing treatments for the same conditions are cheap oral generics, which gives health systems and funders no reason to sponsor fresh trials of an injected alternative.

The strongest claim is accelerated closure of ulcers in the stomach and upper small intestine, reported by several groups, though the one blinded trial run to Western standards found it weaker than the established ulcer medicine it was tested against. Lower opioid requirements during surgery and shifts in blood fats and stress hormones rest on single-group work. Claims about pancreatic complications were contradicted by the largest randomized comparison. Harms are modest and consistent: blood pressure falls, heart rate moves unpredictably, and allergic reactions occur rarely.

The summary is a plausible tissue-protective agent whose evidence has only lately begun to meet modern standards: the first placebo-controlled results, for the inhaled form, have just appeared, while the completed surgical trial’s results remain unpublished.

Top - Benefits - Risks - Protocol